1578 results about "Arginine" patented technology

A pharmaceutical composition comprising a protein arginine methyltransferase 5 (PRMT5) inhibitor and a KRASG12C (Kirsten rat sarcoma viral oncogene homolog glycine-to-cysteine) inhibitor. The pharmaceutical composition can be used for treating various cancers, comprising solid tumors. The combined product can be used for treating any number of diseases associated with PRMT5 and / or KRASG12C.

The invention discloses an arginine decarboxylase diaA enzyme mutant and application thereof in preparation of butanediamine, and belongs to the field of bioengineering. According to the invention, rational charge overturning transformation is simultaneously carried out on a pentamer meridian oligomeric interface and a dimer latitudinal oligomeric interface, so that stable assembly and efficient catalysis of the decamer under the condition of neutral to alkaline pH (7.0-9.0) are realized. Wherein positive charges are introduced into a meridian interface to weaken electrostatic repulsion, and negative charges are introduced into a latitudinal interface to enhance dimer compactness and substrate transfer efficiency. The specific enzyme activity of the representative double mutant AdiAD110K / H736E at pH 8.0 is about 35 times that of a wild type, and the representative double mutant AdiAD110K / H736E keeps a complete decamer state in a pH range of 7.0-9.0. The yield of butanediamine is up to 145.9 g / L under the whole-cell catalysis of the mutant.

The invention belongs to antibacterial materials, and particularly relates to antibacterial modified waterborne polyurethane and a preparation method and application thereof.The preparation method of the antibacterial modified waterborne polyurethane comprises the following steps that polyol and diisocyanate are mixed and subjected to a prepolymerization reaction, and a polyurethane prepolymer is obtained; mixing the polyurethane prepolymer and a chain extender, and carrying out chain extension reaction; in the chain extension reaction, adding the graft and carrying out esterification reaction to obtain a first intermediate; mixing the first intermediate with triethylamine and carrying out neutralization reaction to obtain a second intermediate; and emulsifying the second intermediate in deionized water to obtain the antibacterial modified waterborne polyurethane. Compared with the prior art, the antibacterial waterborne polyurethane has the advantages that the problems of poor intermiscibility, low durability and the like in physical addition and the problems of limited binding objects and weak antibacterial effect in covalent binding in the antibacterial waterborne polyurethane in the prior art are solved. According to the scheme, arginine and chitosan are grafted to a molecular chain of waterborne polyurethane, so that the waterborne polyurethane is endowed with a synergistic antibacterial property.

The invention belongs to the field of skin care products, and particularly relates to an anti-wrinkle and anti-aging composition as well as a preparation method and application thereof, and the anti-wrinkle and anti-aging composition comprises neurotransmitter inhibition peptide, signal peptide, madecassoside, inositol and glycosylglycerol. The neurotransmitter inhibition type peptide is at least three of acetyl hexapeptide-8, arginine / lysine polypeptide, dipeptide diaminobutyrylbenzylamide diacetate and acetyl octapeptide-3, and the signal type peptide is at least two of palmitoyl pentapeptide-4, decapeptide-4 and acetyl tetrapeptide-9. Compared with the prior art, all the components of the anti-wrinkle and anti-aging composition act on different anti-aging pathways and can be matched with one another from multiple aspects of oxidation resistance, inflammation resistance, moisturizing, cell viability enhancement, wrinkle reduction and the like, a more comprehensive and better anti-aging effect is provided, skin aging is comprehensively resisted, the skin is in a more young state, and the anti-wrinkle and anti-aging composition has the advantages that the anti-wrinkle and anti-aging effects are achieved. And the anti-wrinkle and anti-aging composition is small in irritation and good in stability.

The invention provides a collagen freeze-dried product and a preparation method thereof, and belongs to the technical field of biology. In the formula design, through the synergistic effect of the arginine (salt) and the surfactant, denaturation and aggregation of the collagen freeze-dried product in the production process and the storage period are inhibited, the stability of the product is improved, and the prepared collagen freeze-dried product is high in activity, purity and safety. In the freeze-drying process, pre-freezing parameters are optimized, and the nucleation effect of ice crystals in the freezing process of the collagen mixed solution is controlled by regulating and controlling parameters such as temperature and vacuum degree in the freeze-drying process, so that the shapes and the sizes of the crystals in the collagen freeze-dried product are more uniform, the drying time is shortened, and the production efficiency is improved. And the collagen freeze-dried product with uniform pore diameter and excellent appearance is obtained, and the uniformity and stability of batch and inter-batch products are improved.

The invention relates to hydrogel loaded with oxygen self-producing nanoparticles as well as a preparation method and application of the hydrogel. The preparation method comprises the following steps: 1, taking cross-linked methacrylamide silk fibroin and hyaluronic acid modified by arginine-glycine-aspartic acid peptide as base materials, and loading self-oxygen-producing nano particles CaO2 (at) PVP (at) Cu-EGCG, and the self-oxygen-producing nano particles CaO2 (at) PVP (at) Cu-EGCG are prepared by coating Cu-EGCG on calcium peroxide nano particles modified by PVP modified polyvinylpyrrolidone. The hydrogel can improve energy metabolism and regulate immune environment through dual mechanisms, realizes efficient promotion of myocardial repair, and provides a new strategy and thought for tissue regeneration and functional recovery after myocardial infarction.

The invention discloses a full D-type antibacterial peptide with high enzymolysis stability and broad-spectrum antibacterial activity and application thereof. The antibacterial peptide is obtained by sequentially and repeatedly arranging D-type tryptophan, D-type arginine and D-type lysine for four times and carrying out C-terminal amidation; the amino acid sequence of the gene is (D-Trp)-(D-Arg)-(D-Lys)-(D-Trp)-(D-Arg)-(D-Lys)-(D-Trp)-(D-Arg)-(D-Lys)-(D-Trp)-(D-Arg)-(D-Lys)-(D-Trp)-(D-Arg)-(D-Lys)-NH2, and is marked as DWRK-12. The antibacterial peptide shows broad-spectrum antibacterial activity and excellent stability, can effectively resist clinically separated multidrug resistant strains, and keeps high cell selectivity at the same time. Due to the characteristics, the antibacterial peptide has important application value in the aspect of developing novel antibacterial drugs, especially in the field of treatment of infection of multiple drug-resistant bacteria.

The invention discloses a formate dehydrogenase mutant and application of the formate dehydrogenase mutant in catalysis of carbon dioxide reduction, the 223 arginine (Arg) of an amino acid sequence of formate dehydrogenase PsFDH48 derived from Paracoccus sp. MKU1 is mutated into proline (Pro) or the 242 proline (Pro) is mutated into phenylalanine (Phe) through a site-specific mutagenesis technology, and the obtained mutants R223P and P242F have higher catalytic activity and can be applied to catalysis of carbon dioxide reduction. The catalyst can catalyze CO2 to generate formic acid more effectively in vitro, and has potential application value in the aspects of efficient activation of CO2 and further conversion of CO2 into other mono-carbon compounds through cascade reaction.

The invention discloses a cyclic nonapeptide with repairing and anti-oxidation effects and application of the cyclic nonapeptide, the amino acid sequence of the cyclic nonapeptide is cyclic (arginine-glycine-aspartic acid-serine-arginine-lysine-valine-lysine-serine), the prepared cyclic nonapeptide has the repairing and anti-oxidation effects, and the cyclic nonapeptide has the repairing and anti-oxidation effects. The composition can be applied to preparation of cosmetics with repairing and / or anti-oxidation effects.

The invention relates to a multi-effect bionic liposome transdermal repair carrier and a preparation method and application thereof.The multi-effect bionic liposome transdermal repair carrier comprises active ingredients and a nano-carrier, and the active ingredients comprise sialic acid, saccharomycetes / rice fermentation product filtrate, arginine / lysine polypeptide and vitamin E in the mass ratio of (1-10): (2-8): (0.1-1): (0.5-4); the nano-carrier is prepared from the following raw materials: phospholipid, an emulsifier, polyhydric alcohol and water. Compared with the prior art, the anti-aging, whitening and moisturizing composition has the advantages of enhancing skin moisturizing and anti-oxidation effects, promoting collagen synthesis and inhibiting tyrosinase to achieve remarkable anti-aging, whitening and moisturizing effects and the like.

The invention relates to bionic skin barrier cream with a three-layer phospholipid structure and a preparation method of the bionic skin barrier cream, and belongs to the technical field of cosmetics, the bionic skin barrier cream comprises the following raw materials: lecithin, wax ester, triglyceride, composite ceramide, phytosterol oleate, squalane, an antioxidant, polyol, composite amino acid, pyrrolidone carboxylic acid, urea and arginine. A stabilizing agent, a treating agent and the balance of deionized water. The bionic skin barrier cream prepared by the invention has a three-layer phospholipid structure, and compared with a double-layer phospholipid structure in the market, the firmness and hydrophobicity of the double-layer structure are further improved by the added third-layer structure, so that the prepared bionic skin barrier cream has outstanding waterproof, sweat-resistant and light pollution-resistant effects; in addition, the wax ester, the triglyceride, the phytosterol oleate, the pyrrolidone carboxylic acid and the urea selected in the invention have a synergistic effect, and can generate excellent moisturizing and repairing effects and certain protection effects.

The invention discloses a preparation method of perindopril amlodipine tablets, and belongs to the field of pharmacy. The perindopril amlodipine tablet is prepared from the following raw material medicines: arginine perindopril and amlodipine besylate and auxiliary materials: lactose, microcrystalline cellulose, hydrophobic colloidal silicon dioxide and magnesium stearate. The preparation method of the perindopril amlodipine tablet comprises the following steps: weighing according to the prescription amount, crushing and sieving the raw materials for pretreatment, sieving the whole particles of the auxiliary materials for pretreatment, premixing, feeding and total mixing, tabletting and the like. The prepared perindopril amlodipine tablet is relatively good in quality, high in stability and relatively few in waste products.

The invention belongs to the field of feeds, and discloses a biological feed containing a microbial microcapsule preparation and a preparation method of the biological feed. The biological feed is prepared from the following components in parts by weight: 90 to 93 parts of wall-broken rhodopseudomonas palustris powder, 2 to 3 parts of lysine hydrochloride, 0.1 to 0.5 part of methionine, 0.1 to 0.5 part of threonine, 0.3 to 1 part of arginine, 2 to 3 parts of calcium hydrophosphate, 1 to 2 parts of calcium carbonate, 0.5 to 1.2 parts of an antioxidant additive, 0.3 to 0.8 part of modified nano montmorillonite and 1 to 5 parts of a microbial microcapsule preparation. According to the biological feed, the wall-broken rhodopseudomonas palustris serves as basic nutrition and a main microorganism source of the feed and is matched with the compound probiotics of the microorganism micro-capsule preparation, the intestinal nutrition utilization rate is effectively increased, meanwhile, the antioxidant additive is added, and the problems that a single additive is narrow in function and prone to oxidation are solved; the modified nano montmorillonite is added to solve the problem of antagonism of toxin adsorption and mineral absorption.

The present invention belongs to the technical field of biological prevention and treatment for viral diseases. Disclosed in the present invention are a tomato disease-resistant gene mutant, and the use thereof in the prevention and treatment of ToBRFV. It is found in the present invention that mutating the nucleotide at position 1927 of the coding region sequence of tomato Tm-22 gene from G to A, or mutating the amino acid at position 643 of the LRR domain of a protein that is encoded by tomato Tm-22 gene from glycine to arginine can remarkably reduce the accumulation level of ToBRFV capsid protein (CP). The gene (named Tm-22-Mut5) can serve as a novel ToBRFV resistant gene, and also retains the resistance to TMV, ToMV and ToMMV. The Tm-22-Mut5 and a pre-screened Tm-22-Mut3-1 mutant (tyrosine at position 767 of the LRR domain thereof is mutated to phenylalanine) undergo combinatorial mutagenesis to obtain a mutant Tm-22-Mut6. Analysis shows that the Tm-22-Mut6 can remarkably reduce the accumulation level of the ToBRFV capsid protein. Compared with the pFGCTm-22-Mut3-1 mutant obtained by screening in the previous research and the newly obtained mutant Tm-22-Mut5, the Tm-22-Mut6 has further improved resistance to ToBRFV.

The invention discloses a p-nitrophenyl ethyl esterase mutant with high enantioselectivity as well as a construction method and application of the p-nitrophenyl ethyl esterase mutant. The p-nitrophenyl ethyl esterase mutant is obtained by mutating an amino acid sequence of wild p-nitrophenyl ethyl esterase pnbA as shown in SEQ ID NO.1 according to one or a combination of more of the following modes: leucine at the 273rd site is mutated into aspartic acid, phenylalanine at the 314th site is mutated into histidine, and leucine at the 362nd site is mutated into arginine. The mutant pnbA-L273D / F314H / L362R provided by the invention shows optimal catalytic performance (E = 47.16) for racemization-acetic acid pinyl hydrate, the enantiomeric excess value of the mutant is 95.13%, the conversion rate of 1S, 5R-acetic acid pinyl hydrate is 90.42%, the enantioselectivity of the mutant is obviously higher than that of a wild type, and the mutant has great application potential in biological catalytic synthesis of monocyclic monoterpenoid chiral alcohols.

The invention provides a composition with an instant and long-acting anti-aging effect and application thereof. The composition comprises a component A, a component B and a component C, the mass ratio of the raw materials is (1-10): (1-4): (0.05-0.2); the component A is prepared from the following components in parts by weight: 0.01 to 0.5 part of acetyl octapeptide-3, 0.01 to 0.5 part of dipeptide diaminobutyryl benzyl amide diacetate, 0.001 to 0.2 part of arginine / lysine polypeptide, 0.3 to 1 part of caprylyl glycol and 96 to 100 parts of water; the component B is prepared from the following components in parts by weight: 0.001 to 0.2 part of soluble collagen, 5 to 30 parts of glycerol, 0.01 to 0.5 part of sodium dihydrogen phosphate, 0.001 to 0.2 part of disodium hydrogen phosphate and 65 to 100 parts of water; and the component C is tripeptide-29. According to the invention, the quadruple wrinkle fading polypeptide is adopted to block wrinkles in a multi-target full-link manner, so that the product has a very good effect of fading various wrinkles in real time.

The invention belongs to the technical field of bioengineering, and relates to a transaminase mutant, a recombinant genetically engineered bacterium and application of the transaminase mutant in catalytic synthesis of (R)-1-Boc-3-aminopiperidine.The transaminase mutant is obtained by conducting single-point or combined mutation on the 131 site and / or the 197 site of an amino acid sequence shown in SEQ ID NO.2; the mutation sites comprise that the 131 phenylalanine is mutated into aspartic acid, threonine or tyrosine, and / or the 197 lysine is mutated into arginine or leucine. Experimental results show that compared with wild type transaminase, the catalytic activity, the thermal stability and the organic solvent tolerance of the obtained mutants, especially single-point mutants MyTA1-F131Y and MyTA1-K197R and a combined mutant MyTA1-F131Y-K197R, are all remarkably improved, and compared with the wild type transaminase, the catalytic activity, the thermal stability and the organic solvent tolerance of the obtained mutants are all remarkably improved. The mutant MyTA1-F131Y-K197R can be used for efficiently catalyzing asymmetric amination of N-Boc-3-piperidone to synthesize (R)-1-Boc-3-aminopiperidine, the conversion rate of the (R)-1-Boc-3-aminopiperidine after the (R)-1-Boc-3-aminopiperidine reacts for 24 hours under the condition that the substrate concentration is 100 g / L can reach 90% or above, and the mutant MyTA1-F131Y-K197R has a good industrial application prospect.

The preparation method specifically comprises the following steps: sequentially adding arginine and lipoic acid into a gelatin solution to obtain a hydrogel pre-polymerized solution; heating the hydrogel prepolymerization liquid to initiate a lipoic acid ring-opening polymerization cross-linking reaction, and adding a poly (3, 4-ethylenedioxythiophene) dispersion liquid modified by polydopamine to obtain gelatin / polylipoic acid conductive hydrogel; the preparation method comprises the following steps: heating and melting a lipoic acid monomer, then adding a cross-linking agent for reaction, then adding metal salt for stirring, and pouring the obtained yellow transparent liquid on the surface of the gelatin / polylipoic acid conductive hydrogel to obtain the double-layer heterogeneous biological adhesive. The invention also discloses an application of the double-layer heterogeneous biological adhesive in a biomedical adhesive. According to the method, strong interface connection between the two layers is achieved through the similar compatibility principle and the hot melting pouring technology, and layering is avoided during use; and the prepared adhesive has good tissue adhesion, self-repairing performance and biocompatibility.

The invention relates to a Kluyveromyces marxianus strain with high protein yield and application of the Kluyveromyces marxianus strain, which is characterized in that the Kluyveromyces marxianus strain is firstly cultured on a slant, then is transferred into a seed culture medium for seed preparation, and then is inoculated into a fermentation tank, and yeast protein is obtained by adopting index feeding; the bacterial strain is a dominant mutant strain Kluyveromyces marxianus YWX-1, the protein content in a dry thallus reaches 55% or above and is increased by 26% or above compared with that of an original bacterial strain, the bacterial strain can be used for production of single-cell protein, the essential amino acid index (EAAI) value in the protein reaches 1.2, and the bacterial strain is rich in arginine, threonine and lysine and can be applied to production of single-cell protein. These amino acids play a key role in immune regulation, intestinal mucosal barrier function and muscle protein synthesis of young animals. The YWX-1 kluyveromyces marxianus strain has a wide application prospect in the production of neoplasm protein.

The invention relates to the technical field of pharmaceutical preparations, in particular to a stable perindopril amlodipine tablet and a preparation method thereof, and the tablet comprises the following components in percentage by weight: 5.0% of arginine perindopril; 3.5% of amlodipine besylate; 20%-40% of pregelatinized starch; 40%-68% of a microcrystalline cellulose colloidal silicon dioxide compound; 2.5%-6% of a disintegrating agent, wherein the disintegrating agent is selected from one or more of ion exchange resin, sodium alginate and croscarmellose sodium; the pregelatinized starch and the microcrystalline cellulose colloidal silicon dioxide compound are selected as main diluents, so that the Maillard reaction possibly occurring between the lactose and the active pharmaceutical ingredients is completely avoided, the problem of increase of related substances is fundamentally solved, and the stability and the safety of the product are remarkably improved.

The invention discloses a salicylic acid-cyclodextrin-amino acid ternary inclusion compound and a preparation method thereof. The salicylic acid-cyclodextrin-amino acid ternary inclusion compound is formed by salicylic acid, amino acid and a cyclodextrin derivative through non-covalent bond interaction, the cyclodextrin derivative is a cross-linked beta-cyclodextrin polymer, salicylic acid molecules are included in a cavity of the cross-linked beta-cyclodextrin polymer, and the cross-linked beta-cyclodextrin polymer is a cross-linked beta-cyclodextrin polymer. And meanwhile, guanidyl or carboxyl of an amino acid side chain interacts with hydroxyl outside the cross-linked beta-cyclodextrin polymer or an exposed part of an included salicylic acid molecule. According to the invention, a cross-linked beta-cyclodextrin polymer is used, arginine is introduced as a synergist, a salicylic acid-cross-linked beta-cyclodextrin polymer-arginine ternary clathrate compound is constructed, and through charge neutralization and hydrogen bond network synergistic effect, clathration efficiency is significantly improved, and water solubility of salicylic acid is improved.

A pharmaceutical composition comprising a protein arginine methyltransferase 5 (PRMT5) inhibitor and a methionine adenosyltransferase IIα (MAT2A) inhibitor. The pharmaceutical composition can be used for treating various cancers, comprising solid tumors. The combined product can be used for treating any number of diseases associated with PRMT5 and / or MAT2A.

The present application relates to a pyridoxal kinase mutant, a recombinant expression vector and a microbial cell and their applications, and belongs to the technical field of biological catalysis. In order to solve the problem of low product concentration in existing enzyme catalysis, a pyridoxal kinase mutant is provided, the amino acid sequence is selected from the amino acid sequence shown in SEQ ID NO. 1, the lysine at position 229 is mutated to alanine, phenylalanine, methionine, arginine, threonine, histidine, serine, tyrosine, valine, leucine, isoleucine, proline, asparagine, aspartic acid or glutamic acid; the pyridoxal kinase mutant is used for catalyzing pyridoxal to synthesize pyridoxal phosphate, and a recombinant expression vector and a microbial cell can be further formed. The present application has good enzyme activity, high product conversion rate, high concentration of pyridoxal phosphate obtained, and the concentration of the product catalyzed by the wild-type pyridoxal kinase to phosphorylate pyridoxal is obviously improved.

The invention belongs to the technical field of traditional Chinese medicines and cosmetics, and particularly relates to eutectic resveratrol, a liposome thereof, a preparation method and application of the eutectic resveratrol. The eutectic resveratrol is prepared from the following raw materials: resveratrol, amino acid and glycerol; the amino acid is selected from one of proline, lysine and arginine. The eutecticevaporate resveratrol liposome is prepared from the following raw materials: soybean phospholipid, cholesterol and eutecticevaporate resveratrol, the mass ratio of the soybean phospholipid to the cholesterol is (1-9): 1, and the mass ratio of the sum of the mass of the soybean phospholipid and the cholesterol to the mass of the eutecticevaporate resveratrol is 1: (0.5-2). A method capable of improving the solubility and stability of resveratrol is found, the eutectic resveratrol liposome which is stable in particle size and PDI and excellent in zeta potential and has certain anti-oxidation and antibacterial performance is prepared, the solubility, stability and bioavailability of resveratrol (RES) are improved, and the resveratrol liposome is suitable for being used as an anti-inflammatory drug. And a new thought is provided for further development and application research of resveratrol (RES).

Disclosed is a pharmaceutical composition, comprising a protein arginine methyltransferase 5 (PRMT5) inhibitor and an epidermal growth factor receptor tyrosine kinase (EGFR) inhibitor. The pharmaceutical composition can be used to treat various cancers, including solid tumors. The combination product can be used to treat any number of diseases associated with PRMT5 and / or EGFR.

The invention discloses a repairing mask containing Chinese rose hydrolat, which is prepared from the following components: the Chinese rose hydrolat, pure water, 1, 3-butanediol, allantoin, carbomer, sodium hyaluronate, xanthan gum, arginine, nicotinamide, 1, 2-pentanediol, 1, 2-hexanediol, octylene glycol, menthol, a carbohydrate gum composition, squalane nanoemulsion and a wrapping freshener. The invention discloses a production process of a repairing mask containing Chinese rose hydrolat. The repairing mask containing the Chinese rose hydrolat has the advantages of moisturizing, soothing and calming, nourishing skin, whitening and fading spots.

The invention provides a chitosan-based hydrogel nano material as well as a preparation method and application thereof, and belongs to the technical field of chemical synthesis and biomedicine. The method comprises the following steps: firstly, dissolving pyropheophorbide A and copper chloride in a solvent, and carrying out heating reflux reaction to obtain PPA-Cu; then, the PPA-Cu is grafted to chitosan (CS), and CS-PPA-Cu is obtained; arginine is added into the prepared CS-PPA-Cu solution, and CS-PPA-Cu (at) Arg is obtained; finally, the CS-PPA-Cu-coated Arg and the prepared PF solution are mixed and stirred, standing is conducted at the room temperature, and the chitosan-based CS-PPA-Cu / PF-coated Arg hydrogel is obtained. The hydrogel nano material has excellent bioluminescence performance, and can specifically recognize the position of wound inflammation. The prepared hydrogel nano material has the combined antibacterial ability of photodynamic, photothermal and NO gas release, and achieves the effect of promoting wound healing.

The invention discloses an application of lactobacillus mucosa LMSJ001 or a metabolite agmatine of the lactobacillus mucosa LMSJ001 in preparation of a medicine for improving intestinal aging, and the application research of the lactobacillus mucosa LMSJ001 in a constructed aging mouse model finds that the lactobacillus mucosa LMSJ001 can be used for preparing a medicine for improving intestinal aging. Therapeutic gavage and application of Lactobacillus mucosa LMSJ001 in colon organs for intervention can significantly improve aging indexes, alleviate histological aging performance, promote intestinal peristalsis of aged mice, reduce secretion of inflammatory factors of the aged mice, improve intestinal epithelial barrier functions of the aged mice and improve intestinal dryness of the aged mice. The lactobacillus mucosa LMSJ001 can generate a metabolite agmatine through arginine decarboxylase, and agmatine can improve related indexes of proliferation and differentiation of intestinal stem cells and reduce expression of related indexes of senescence. Based on the unique functions, the lactobacillus mucosa LMSJ001 or the metabolite agmatine of the lactobacillus mucosa LMSJ001 can be cooperated or complemented with other means, is used for preparing pharmaceutical compositions or detection kits and the like, and has very wide application prospects.

Provided herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof. The provided compounds are useful Protein arginine N-methyltransferase 5 (PRMT5) inhibitors. Also, disclosed are pharmaceutical compositions comprising such compounds and methods of making such compounds. Additional utilities and advantages are described herein.

The application discloses a formic acid dehydrogenase mutant and application thereof in catalyzing carbon dioxide reduction. Paracoccus The formic acid dehydrogenase from sp.MKU1 is mutated by a site-directed mutation technology Ps The arginine (Arg) at the 223th position of the FDH48 amino acid sequence is mutated into proline (Pro) or the proline (Pro) at the 242th position is mutated into phenylalanine (Phe), and the obtained mutants R223P and P242F have higher catalytic activity, can more effectively catalyze CO2 to generate formic acid in vitro, and have potential application values in efficient activation of CO2 and further conversion into other one-carbon compounds through cascade reactions.